EGFR-RAD51 fusion	Lung Adenocarcinoma	EGFR-RAD51 fusion	Lung Adenocarcinoma	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR-RAD51 fusion	Lung Adenocarcinoma	EGFR-RAD51 fusion	Lung Adenocarcinoma	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4
EGFR-RAD51 fusion	Non Small Cell Lung Cancer	EGFR-RAD51 fusion	Non Small Cell Lung Cancer	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4
EGFR-RAD51 fusion	Non Small Cell Lung Cancer	EGFR-RAD51 fusion	Non Small Cell Lung Cancer	gefitinib Sensitive: C4 – Case Studies gefitinib Sensitive : C4	gefitinib Sensitive: C4 – Case Studies gefitinib Sensitive : C4
EGFR-RAD51 fusion	Non Small Cell Lung Cancer	EGFR-RAD51 fusion	Non Small Cell Lung Cancer	osimertinib + erlotinib Sensitive: C4 – Case Studies osimertinib + erlotinib Sensitive : C4	osimertinib + erlotinib Sensitive: C4 – Case Studies osimertinib + erlotinib Sensitive : C4

EGFR-RAD51 fusion

Associations